» Articles » PMID: 18299685

The Kidney in Thrombotic Thrombocytopenic Purpura

Overview
Journal Minerva Med
Specialty General Medicine
Date 2008 Feb 27
PMID 18299685
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The kidney is commonly affected in thrombotic thrombocytopenic purpura (TTP), a multi-system disorder with microvascular thrombosis of the capillaries and arterioles. Nevertheless, due to difference in its diagnostic criteria, the frequency and severity of renal dysfunction in TTP remains controversial. Recent studies indicate that the severe deficiency of a von Willebrand factor (VWF) cleaving protease, ADAMTS13, is the main cause of platelet thrombosis in TTP; it is now possible to define TTP at the molecular level. Among patients with acquired TTP due to inhibitory antibodies of ADAMTS13, renal dysfunction is usually mild; oliguria, fluid overload, hypertension, and need of dialysis support are infrequent. When any of these complications occur, one must re-examine the diagnosis of TTP and consider the possibility that the patient has another cause for these complications. In a patient with hereditary TTP, acute renal failure may ensue. However, the renal dysfunction is mostly reversible if the patients are promptly treated with plasma to replenish ADAMTS13. Patients with TTP, particularly of the hereditary type, may develop chronic renal failure. This complication may be a consequence of repeated insults by overt or subclinical microvascular thrombosis to the kidney, or it may have a separate cause. Therapy of hereditary TTP should aim not only to prevent acute exacerbations but also to minimize the risk of irreversible renal injury.

Citing Articles

The Development of Neurological Damage in a Patient With Thrombotic Thrombocytopenic Purpura and Legionnaires' Disease: A Case Report.

Chen V, Gulia K, How-Volkman C, Geraghty J, Lui F Cureus. 2023; 15(7):e42277.

PMID: 37605684 PMC: 10440192. DOI: 10.7759/cureus.42277.


[Clinical diagnosis and treatment of hereditary thrombocytopenia and purpura: a report of five cases and literature review].

Lyu X, Yin J, Kong D, Tian H, Li Y, Qyu Q Zhonghua Xue Ye Xue Za Zhi. 2023; 44(1):43-47.

PMID: 36987722 PMC: 10067373. DOI: 10.3760/cma.j.issn.0253-2727.2023.01.008.


Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.

Selvakumar S, Liu A, Chaturvedi S Front Med (Lausanne). 2023; 10:1137019.

PMID: 36926315 PMC: 10011081. DOI: 10.3389/fmed.2023.1137019.


Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Fodil S, Zafrani L J Clin Med. 2022; 11(4).

PMID: 35207375 PMC: 8874413. DOI: 10.3390/jcm11041103.


What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.

Halimi J, Thoreau B, Von Tokarski F, Bauvois A, Gueguen J, Goin N BMC Nephrol. 2022; 23(1):39.

PMID: 35057750 PMC: 8781095. DOI: 10.1186/s12882-022-02672-3.


References
1.
Tsai H, Shulman K . Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003; 70(3):183-5. DOI: 10.1034/j.1600-0609.2003.00026.x. View

2.
Nicol K, Shelton B, Knovich M, Owen J . Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura. Am J Hematol. 2003; 74(3):170-4. DOI: 10.1002/ajh.10418. View

3.
Tsai H . Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003; 29(5):479-88. DOI: 10.1055/s-2003-44556. View

4.
Manea M, Kristoffersson A, Schneppenheim R, Saleem M, Mathieson P, Morgelin M . Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007; 138(5):651-62. DOI: 10.1111/j.1365-2141.2007.06694.x. View

5.
Bukowski R . Thrombotic thrombocytopenic purpura: a review. Prog Hemost Thromb. 1982; 6:287-337. View